Pharmacokinetics of protein- and nucleotide-based drugs

Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids

Volumn , Issue , 2004, Pages 275-294

  Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885525737     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (79)

1. Arlington, S., Barnett, S., Hughes, S., and Palo, J., Pharma P 2010: The Threshold to Innovation. IBM Business Consulting Services, Somers, New York, 2002.
2. Meibohm, B., and Derendorf, H., Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int. J. Clin. Pharmacol. Ther., 1997; 35: 401-413.
3. Levy, G., Kinetics of drug action: An overview. J. Allergy Clin. Immunol., 1986; 78: 754-761.
4. Meibohm, B., and Derendorf, H., Pharmacokinetic/pharmacodynamic studies in drug product development. J. Pharm. Sci., 2002; 91: 18-31.
5. Gibaldi, M., and Perrier, D., Pharmacokinetics, 2nd edn. Marcel Dekker Inc., New York (1982).
6. Rowland, M., and Tozer, T., Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. Williams & Wilkins, Media, PA, 1993.
7. Atkinson, A., Daniels, C., Dedrick, R., Grudzinskas, C., and Markey, S., Principles of Clinical Pharmacology. Academic Press, San Diego, 2001.
8. Levy, R. H., and Bauer, L. A., Basic pharmacokinetics. Ther. Drug Monit., 1986; 8: 47-58.
9. Bjomsson, T. D., Practical uses of individual pharmacokinetic parameters in drug development and clinical practice: examples and simulations. Eur. J. Drug Metab. Pharmacokinet., 1997; 22: 1-14.
10. Derendorf, H., and Meibohm, B., Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm. Res., 1999; 16: 176-185.
11. Wills, R. J., and Ferraiolo, B. L., The role of pharmacokinetics in the development of biotechnologically derived agents. Clin. Pharmacokinet., 1992; 23: 406-414.
12. Herbst, R. S., Kim E. S., and Harari P. M., IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin. Biol. Ther., 2001; 1: 719-732.
13. Colburn, W., Peptide, peptoid, and protein pharmacokinetics/pharmacodynamics. In: Garzone, P., Colburn, W., and Mokotoff, M. (eds), Peptides, Peptoids, and Proteins. Harvey Whitney Books: Cincinnati, OH, 1991, pp. 94-115.
14. McMartin, C., Pharmacokinetics of peptides and proteins: opportunities and challenges. Adv. Drug. Res., 1992; 22: 39-106.
15. Fasano, A., Novel approaches for oral delivery of macromolecules. J. Pharm. Sci, 1998; 87: 1351-1356.
16. Shen, W. C., Oral peptide and protein delivery: unfulfilled promises? Drug Discov. Today, 2003; 8: 607-608.
17. Mahato, R. I., Narang A. S., Thoma, L., and Miller, D. D., Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst., 2003; 20: 153-214.
18. Lee, H. J., Protein drug oral delivery: the recent progress. Arch. Pharm. Res, 2002; 25: 572-584.
19. Pauletti, G. M., Gangwar, S., Siahaan, T. J., Jeffrey, A., and Borchardt, R. T., Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv. Drug. Deliv. Rev., 1997; 27: 235-256.
20. Lee, V. H. L., Problems and solutions in peptide and protein drug delivery. In: Garzone, P., Colburn, W., and Mokotoff, M. (eds), Peptides, Peptoids, and Proteins. Harvey Whitney Books: Cincinnati, OH, 1991, pp. 81-92.
21. Porter, C. J., and, Charman, S. A., Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci., 2000; 89: 297-310.
22. Supersaxo, A., Hein, W. R., and Steffen, H., Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res., 1990; 7: 167-169.
23. Supersaxo, A., Hein, W., Gallati, H., and Steffen, H., Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm. Res., 1988; 5: 472-476.
24. Zito, S. W., Pharmaceutical Biotechnology: a Programmed Text. Technomic Pub. Co.: Lancaster, PA, 1997.
25. Chiang, J., Gloff, C. A., Yoshizawa, C. N., and Williams, G. J., Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Pharm. Res., 1993; 10: 567-572.
26. Mould, D. R. et al., A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 1999; 66: 246-257.
27. Kageyama, S. et al., Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler. Thromb. Vasc. Biol., 2002; 22: 187-192.
28. Tanswell, P., Modi, N., Combs D., and Danays, T., Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin. Pharmacokinet., 2002; 41: 1229-1245.
29. Mohler, M, et al., Altered pharmacokinetics of recombinant human deoxyribonuclease in rats due to the presence of a binding protein. Drug. Metab. Dispos., 1993; 21: 71-75.
30. Toon, S., The relevance of pharmacokinetics in the development of biotechnology products. Eur. J. Drug Metab. Pharmacokinet., 1996; 21: 93-103.
31. Eppler, S. M., et al., A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin. Pharmacol. Ther., 2002; 72: 20-32.
32. Piscitelli, S. C., Reiss, W. G, Figg, W. D., and Petros, W. P., Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. Clin. Pharmacokinet. 1997; 32: 368-381.
33. Banks, R. E. et al., Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects. Cytokine, 2000; 12: 388-396.
34. Montero-Julian, F. A., Klein, B., Gautherot, E., and Brailly, H., Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood, 1995; 85: 917-924.
35. Wills, R., A kinetic/dynamic perspective of a peptide and protein: GRF and rHuIFN-alpha-2a. In: Garzone, P., Colburn, W., and Mokotoff, M. (eds), Peptides, Peptoids, and Proteins. Harvey Whitney Books, Cincinnati, OH, 1991, pp. 117-127.
36. Edwards, A., Daniels, B. S., Deen, W. M., Ultrastructural model for size selectivity in glomerular filtration. Am. J. Physiol., 1999; 276: F892-902.
37. Deen, W. M., Lazzara, M. J., and Myers B. D., Structural determinants of glomerular permeability. Am. J. Physiol. Renal. Physiol., 2001; 281: F579-596.
38. Maack, T., Park, C., and Camargo, M., Renal filtration, transport and metabolism of proteins. In: Seldin, D., and Giebisch, G. (eds), The Kidney. Raven Press, New York, 1985, pp. 1773-1803.
39. Andersen, S. R. et al., Disposition of recombinant human interleukin-10 in subjects with various degrees of renal function. J. Clin. Pharmacol., 1999; 39: 1015-1020.
40. Anderson P. M., and Sorenson, M. A., Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin. Pharmacokinet., 1994; 27: 19-31.
41. Takagi, A., Masuda, H., Takakura, Y., and Hashida, M., Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J. Pharmacol. Exp. Ther., 1995; 275: 537-543.
42. Rabkin, R., Ryan, M. P., and Duckworth, W. C., The renal metabolism of insulin. Diabetologia, 1984; 27: 351-357.
43. Carone, F. A., Peterson, D. R., and Flouret, G., Renal tubular processing of small peptide hormones. J. Lab. Clin. Med., 1982; 100: 1-14.
44. Inui, K., Terada, T., Masuda, S., Saito, H., Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2. Nephrol. Dial. Transplant., 2000; 15, Suppl 6: 11-13.
45. Krogsgaard Thomsen, M. et al., Studies on the renal kinetics of growth hormone (GH) and on the GH receptor and related effects in animals. J. Pediatr. Endocrinol., 1994; 7: 93-105.
46. Johnson, V., and Maack, T., Renal extraction, filtration, absorption, and catabolism of growth hormone. Am. J. Physiol. 1977; 233: F185-196.
47. Bu, G., Williams, S., Strickland, D. K., Schwartz, A. L., Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA, 1992; 89: 7427-7431.
48. Smedsrod, B., and Einarsson, M., Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver. Thromb. Haemost., 1990; 63: 60-66.
49. Levy, G., Pharmacologic target-mediated drug disposition. Clin. Pharmacol. Ther, 1994; 56: 248-252.
50. Bartocci, A. et al., Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc. Natl. Acad. Sci. USA, 1987; 84: 6179-6183.
51. Bauer, R. J., et al., Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats. J. Pharmacol. Exp. Ther., 1994; 268: 152-158.
52. Tokuda, Y. et al., Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br. J. Cancer, 1999; 81: 1419-1425.
53. Kobayashi, H. et al., Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macro-molecular contrast agent G6-(1B4M-Gd)(256). Cancer Res., 2002; 62: 860-866.
54. Working, P., and Cossum, P., Clinical and preclinical studies with recombinant human proteins: effect of antibody production. In: Garzone, P., Colburn, W., and Mokotoff, M. (eds), Peptides, Peptoids, and Proteins. Harvey Whitney Books, Cincinnati, OH, 1991, pp. 158-168.
55. Batra, S. K., et al., Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr. Opin. Biotechnol., 2002; 13: 603-608.
56. Herbst, R. S., and Langer C. J., Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol., 2002; 29: 27-36.
57. Harris, J. M., Martin, N. E., and Modi, M., Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet., 2001; 40: 539-551.
58. Molineux, G., Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy, 2003; 23: 3S-8S.
59. Walsh, S., Shah, A., and Mond, J., Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Anti-microb. Agents. Chemother., 2003; 47: 554-558.
60. Graham, M. L., Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev, 2003; 55: 1293-1302.
61. Dvorchik, B. H., The disposition (ADME) of antisense oligonucleotides. Curr. Opin. Mol. Ther, 2000; 2: 253-257.
62. Geary, R. S., Yu, R. Z., and Levin A. A., Pharmacokinetics of phosphoro-thioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs., 2001; 2: 562-573.
63. Isis Pharmaceuticals, New data on capsule form of ISIS 104838 demonstrate antisense drugs can be administered orally, Press Release: Toronto, Canada, 2002.
64. Agrawal, S., Temsamani, J., Galbraith, W., and Tang, J., Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet., 1995; 28: 7-16.
65. Geary, R. S. et al., Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleo-tides. Anticancer Drug Des., 1997; 12: 383-393.
66. Yacyshyn, B. R. et al., Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeox-ynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease. Gut, 2002; 51: 30-36.
67. Yacyshyn, B. R. et al., Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn’s disease. Aliment. Pharmacol. Ther., 2002; 16: 1761-1770.
68. Sereni, D. et al., Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects. J. Clin. Pharmacol., 1999; 39: 47-54.
69. Yu, R. Z. et al., Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J. Pharm. Sci., 2001; 90: 182-193.
70. Levin, A. A., A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta., 1999; 1489: 69-84.
71. Crooke, S. T. et al., Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther., 1996; 277: 923-937.
72. 0-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J. Pharmacol. Exp. Ther, 2002; 303: 1334-1343.
73. Nishikawa, M., Takemura, S., Takakura, Y., and Hashida, M., Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(L-lysine) complexes by controlling their physicochemical properties. J. Pharmacol. Exp. Ther., 1998; 287: 408-415.
74. Houk, B. E., Martin, R., Hochhaus, G., and Hughes, J. A., Pharmacokinetics of plasmid DNA in the rat. Pharm. Res., 2001; 18: 67-74.
75. Takakura, Y., Nishikawa, M., Yamashita, F., and Hashida, M., Development of gene drug delivery systems based on pharmacokinetic studies. Eur. J. Pharm. Sci., 2001; 13: 71-76.
76. Kawabata, K., Takakura, Y., and Hashida, M., The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res., 1995; 12: 825-830.
77. Mahato, R. I., Kawabata, K., Takakura, Y., and Hashida, M., In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. J. Drug Target., 1995; 3: 149-157.
78. Mahmood, I., Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J. Pharm. Sci., 2004; 93: 177-185.
79. CDER/FDA, Exposure Response Relationships: Guidance for Industry US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, 2003.